Company Overview of PhaseRx, Inc.
PhaseRx, Inc. develops RNA nanomedicines for the treatment of orphan diseases. The company’s pipeline includes RNA therapeutics to treat unmet medical needs, including inherited metabolic diseases and liver cancer. It develops nanomedicines based on its SMARTT Polymer Technology that offers the ability to deliver messenger RNA (mRNA) therapeutics predictably to selected tissues in vivo, thereby unlocking the value of mRNA as a new therapeutic modality. The company was founded in 2006 and is based in Seattle, Washington.
410 West Harrison Street
Seattle, WA 98119
Founded in 2006
Key Executives for PhaseRx, Inc.
Co-Founder, Chief Executive Officer, President and Director
Compensation as of Fiscal Year 2015.
PhaseRx, Inc. Key Developments
PhaseRx, Inc. Announces Board and Management Changes
Feb 9 16
PhaseRx, Inc. announced the strengthening of its Board of Directors and leadership team. This includes the appointments of Michelle Griffin (Burris) to the Board of Directors and
Helen Tsui as Vice President of Finance, as well as the promotion of Michael Houston, Ph.D., to Chief Scientific Officer. Michelle Griffin is a seasoned veteran of the biotechnology industry, both as a board member and in executive management. She currently serves as Principal of the Pacific Biotechnology Consulting Group as well as operations consultant for Oncogenex Pharmaceuticals, where she previously served as Executive Vice President. She has served as Senior Vice President and Chief Operating Officer at Trubion Pharmaceuticals and Senior Vice President and Chief Financial Officer at Corixa Corp. In addition, she has held strategic and operations planning positions with The Boeing Co. Griffin currently serves on the Virginia Mason Health System and Virginia Mason Medical Center Boards of Directors as well as on the executive advisory board for the Albers School of Business and Economics at Seattle University Helen Tsui brings more than twenty years of financial management experience, including SEC reporting, M&A due diligence and accounting operations to PhaseRx. She previously served as Vice President, Corporate Controller for Dendreon Corporation. During the course of her 15 years at Dendreon, Tsui managed all accounting functions, SEC reporting and led multiple cross functional teams to support compliance and reporting efforts. Prior to Dendreon, Tsui worked as corporate controller and accounting manager for Data Dimensions and as a senior auditor for BDO Seidman. Tsui received her BA in Business Administration with a major in accounting from the University of Washington and has passed the Certified Public Accountant exam. Dr. Houston Joined PhaseRx in January 2014 as Vice President, Therapeutics Development. Prior to that he served as Vice President, Chemistry and Formulations for Marina Biotech where he focused on the development of siRNAS and single stranded oligonucleotides. Dr. Houston has also served at Ascent Therapeutics as Vice President, Preclinical Chemistry and CMC; at MDRNA, Inc. as Vice President, Chemistry & Formulations; and at Nastech Pharmaceuticals as Senior Director, Chemistry and Formulations.
PhaseRx, Inc. Presents at Boston Biotech East West CEO Conference, Jan-09-2016 09:55 AM
Jan 1 16
PhaseRx, Inc. Presents at Boston Biotech East West CEO Conference, Jan-09-2016 09:55 AM. Venue: Four Seasons Hotel, 757 Market St., San Francisco, CA 94103, United States. Speakers: Robert W. Overell, Co-Founder, Chief Executive Officer, President and Director.
PhaseRx, Inc. Presents at Boston CEO Conference, May-27-2015 04:00 PM
Apr 16 15
PhaseRx, Inc. Presents at Boston CEO Conference, May-27-2015 04:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Robert W. Overell, Co-Founder, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 21, 2015